Chinese Regulators Report Steady Progress In Promoting Innovation - DIA China Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's State FDA has made steady progress in meeting the challenges of drug supervision while at the same time encouraging innovation and ensuring safety, SFDA Deputy Commissioner Wu Zhen told executives and scientists during the second Drug Information Association China annual meeting in Beijing this week